Registered title, quoted from ClinicalTrials.gov
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma
An open trial on lymphoma, registered on ClinicalTrials.gov. Led by Fudan University Shanghai Cancer Center; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07768943, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Histologically confirmed extranodal NK/T-cell lymphoma, nasal type, according to the 2022 World Health Organization classification.
Inclusion criterion 2
Lugano 2014 stage IE or IIE disease with a primary site in the upper aerodigestive tract, including but not limited to the nasal cavity, paranasal sinuses, nasopharynx, oropharynx, or oral cavity.
Inclusion criterion 4
Another active malignancy within the previous 6 months requiring surgery, radiotherapy, or systemic anticancer therapy.
Exclusion criterion 14
Eastern Cooperative Oncology Group performance status of 0 to 2.
Inclusion criterion 7
Absolute neutrophil count at least 1.0 x 10\^9/L.
Inclusion criterion 9
Platelet count at least 75 x 10\^9/L.
Inclusion criterion 10
Hemoglobin at least 90 g/L.
Inclusion criterion 11
No granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion within 14 days before enrollment.
Inclusion criterion 12
Total bilirubin no greater than 1.5 times the upper limit of normal.
Inclusion criterion 13
Serum creatinine no greater than 1.5 times the upper limit of normal.
Inclusion criterion 15
Human immunodeficiency virus infection, active hepatitis C virus infection, or hepatitis B virus infection with HBV DNA greater than 10\^3/mL.
Exclusion criterion 5
Pregnancy or breastfeeding.
Exclusion criterion 11
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: scans and measurable lesions.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07768943, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Age 18 to 75 years, inclusive.
- Histologically confirmed extranodal NK/T-cell lymphoma, nasal type, according to the 2022 World Health Organization classification.
- Diagnosis confirmed by institutional or central pathological review. Tumor tissue must be adequate for morphological assessment, immunohistochemistry, and Epstein-Barr virus-encoded RNA in situ hybridization.
- Lugano 2014 stage IE or IIE disease with a primary site in the upper aerodigestive tract, including but not limited to the nasal cavity, paranasal sinuses, nasopharynx, oropharynx, or oral cavity.
- At least one disease lesion evaluable by PET/CT at baseline.
- No previous chemotherapy, radiotherapy, immunotherapy, or other antitumor biological therapy for lymphoma.
- Eastern Cooperative Oncology Group performance status of 0 to 2.
- Adequate organ function, including:
- Absolute neutrophil count at least 1.0 x 10\^9/L.
- Platelet count at least 75 x 10\^9/L.
- Hemoglobin at least 90 g/L.
- No granulocyte colony-stimulating factor, platelet transfusion, or red blood cell transfusion within 14 days before enrollment.
- Total bilirubin no greater than 1.5 times the upper limit of normal.
- Alanine aminotransferase and aspartate aminotransferase no greater than 2 times the upper limit of normal.
- Serum creatinine no greater than 1.5 times the upper limit of normal.
- Fibrinogen at least 1.5 g/L.
- Left ventricular ejection fraction at least 50%.
- Ability to understand the study and provide written informed consent.
- Willingness to comply with protocol treatment, follow-up, laboratory testing, imaging assessments, and biospecimen collection.
Exclusion Criteria:
- Diagnosis not meeting the 2022 World Health Organization criteria for extranodal NK/T-cell lymphoma or not confirmed after pathological review.
- Lugano stage III or IV disease or distant organ involvement inconsistent with localized early-stage disease.
- Primary disease outside the upper aerodigestive tract or predominantly systemic or widespread extranodal disease.
- Previous lymphoma-directed chemotherapy, radiotherapy, immunotherapy, or other systemic antitumor treatment.
- Human immunodeficiency virus infection, active hepatitis C virus infection, or hepatitis B virus infection with HBV DNA greater than 10\^3/mL.
- History of pancreatitis or pancreatic disease considered unsuitable for pegaspargase treatment.
- Acute or systemic infection requiring intravenous anti-infective treatment.
- Severe complications including hemophagocytic lymphohistiocytosis or disseminated intravascular coagulation.
- Significant organ dysfunction, including respiratory failure, chronic congestive heart failure of New York Heart Association class II or higher, decompensated hepatic or renal dysfunction, uncontrolled hypertension or diabetes despite appropriate treatment, or cardiovascular or cerebrovascular thrombosis or bleeding within the previous 6 months.
- Active autoimmune disease or another condition considered by the investigator to make immune checkpoint inhibitor treatment unsuitable.
- Pregnancy or breastfeeding.
- Participants of reproductive potential who are unwilling to use adequate contraception.
- Known severe hypersensitivity to any study drug or its excipients.
- Another active malignancy within the previous 6 months requiring surgery, radiotherapy, or systemic anticancer therapy.
- Severe psychiatric disorder, poor adherence, or another condition that, in the investigator's judgment, would prevent completion of protocol treatment or follow-up.
- Current use of another investigational drug or participation in another interventional clinical trial within 4 weeks before enrollment.
Quoted from ClinicalTrials.gov, NCT07768943, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07768943, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.